Knee Artery Embolization for Osteoarthritis
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it does mention that participants should have been on non-surgical therapy like joint injections, oral NSAIDs, or opioid analgesia for at least one month before joining.
What data supports the effectiveness of the treatment Knee Artery Embolization for Osteoarthritis?
Research suggests that genicular artery embolization (a procedure that blocks blood flow to certain knee arteries) may help reduce pain in people with knee osteoarthritis, especially when other treatments haven't worked. Some studies indicate it could be a promising option for managing symptoms.12345
Is knee artery embolization safe for treating osteoarthritis?
How is the treatment geniculate artery embolization different from other treatments for knee osteoarthritis?
Geniculate artery embolization (GAE) is a unique treatment for knee osteoarthritis that involves blocking specific blood vessels in the knee to reduce pain and inflammation, unlike traditional treatments that often rely on medications or surgery. This minimally invasive procedure targets the blood supply to the inflamed areas, potentially offering relief for patients with refractory pain who do not respond well to other therapies.12479
What is the purpose of this trial?
The objective of this study is to investigate if MRI can be used to evaluated effect of knee artery embolization for knee osteoarthritis. Participants be evaluated in clinic, obtain a knee MRI, undergo embolization of the symptomatic knee, and follow up in clinic at 1, 6, and 12 months after embolization. A second MRI is obtained 6 months after embolization. Participants will keep a record of their pain level and treatment and answer questionnaires at each visit.In addition, this study aims to determine the effects of knee artery embolization on the amount of opioid (pain reliever drugs) needed to manage osteoarthritis-associated pain and change in quality of life.
Research Team
Andre Uflacker, MD
Principal Investigator
Medical University of South Carolina
Eligibility Criteria
This trial is for adults aged 25-90 with knee osteoarthritis, who've tried non-surgical pain treatments like injections or NSAIDs. They must be able to consent and have no MRI contraindications, severe kidney issues, malignancy in the knee, rheumatoid arthritis/gout, recent septic arthritis, or past major knee surgery.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo geniculate artery embolization of the symptomatic knee
Follow-up
Participants are monitored for safety and effectiveness after treatment, with follow-up visits at 1, 6, and 12 months post-embolization
MRI Evaluation
Participants obtain a knee MRI to evaluate the effect of embolization, with a second MRI at 6 months
Treatment Details
Interventions
- dynamic contrast enhanced MRI
- geniculate artery embolization
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical University of South Carolina
Lead Sponsor
Bayer
Industry Sponsor
Bill Anderson
Bayer
Chief Executive Officer since 2023
BSc in Chemical Engineering from the University of Texas, MSc in Chemical Engineering and Management from MIT
Michael Devoy
Bayer
Chief Medical Officer since 2014
MD, PhD